Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

Revelation Biosciences, Inc.

We develop immunologic therapeutics and diagnostics designed to make the world a healthier place 


	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables		865.90K -	596.26K 31.14%	554.21K 7.05%	1.36M 145.38%
accumulated other comprehensive income loss
cash and cash equivalents		4.49M -	1.27M 71.62%	5.25M 312.09%	11.99M 128.28%
cash and short term investments		4.49M -	1.27M 71.62%	5.25M 312.09%	11.99M 128.28%
common stock		2.29K -	2.31K 0.70%	683 70.42%	265 61.20%
deferred revenue
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt
long term investments
net debt		-4.49M -	-1.26M 72.00%	-5.25M 317.57%	-11.99M 128.28%
net receivables
other assets		-73.51M -
other current assets		128K -	637.34K 397.92%	73.13K 88.53%	84.69K 15.81%
other current liabilities	26.31K -	342.88K 1,203.26%	1.53M 345.84%	3.90M 154.91%	4.20M 7.91%
other liabilities		-2.91M -	-2.91M 0%	-554.21K 80.96%
other non current assets	22.67K -	73.51M 324,150.87%			71.13K -
other non current liabilities		2.91M -	2.91M 0%	554.21K 80.96%
othertotal stockholders equity		5.54M -	6.93M 25.24%	26.40M 280.74%	32.11M 21.65%
preferred stock		403.73K -	7.48M 1,753.19%
property plant equipment net			130.14K -	90.13K 30.74%	65.08K 27.79%
retained earnings	-3.64K -	-2.53M 69,456.40%	-14.52M 473.70%	-25.35M 74.60%	-25.47M 0.47%
short term debt			16.75K -
short term investments		525.29K -
tax assets
tax payables
total assets	22.67K -	4.62M 20,280.22%	2.04M 55.80%	5.50M 169.48%	12.21M 121.91%
total current assets		4.62M -	1.91M 58.62%	5.41M 183.11%	12.08M 123.09%
total current liabilities	26.31K -	1.21M 4,494.53%	2.14M 77.18%	4.45M 107.83%	5.56M 25.03%
total debt			16.75K -
total investments		525.29K -
total liabilities	26.31K -	1.21M 4,494.53%	2.14M 77.18%	4.45M 107.83%	5.56M 25.03%
total liabilities and stockholders equity	22.67K -	4.62M 20,280.22%	2.04M 55.80%	5.50M 169.48%	12.21M 121.91%
total non current assets	22.67K -	73.51M 324,150.87%	130.14K 99.82%	90.13K 30.74%	136.22K 51.13%
total non current liabilities		2.91M -	2.91M 0%	554.21K 80.96%
total stockholders equity	-3.64K -	3.41M 93,877.46%	-99.47K 102.92%	1.05M 1,158.06%	6.65M 531.64%

COM:REVBIOSCIENCES

Revelation Biosciences, Inc.

Last Close

0.75

22/11 21:00

Market Cap

2.91M

Beta: -

Volume Today

116.70K

Avg: -

Preview